B · Normal
[Hanyu Pharmaceutical: Teriparatide (H) Injection obtained the Drug Registration Certificate] On November 13, Hanyu Pharmaceutical (300199.SZ) announced that the company recently received the "Drug Registration Certificate" approved and issued by the State Food and Drug Administration, and Teriparatide (H) Injection was approved for marketing. This drug is the first domestically approved preparation based on a chemical synthesis route and is suitable for the treatment of osteoporosis in postmenopausal women who are at high risk of fractures. This approval will further enrich the company's peptide preparation product pipeline and enhance its market competitiveness in the field of orthopedic treatment.
Comments